Inmed pharmaceuticals signs definitive agreement to acquire baymedica, a leading commercial manufacturer of rare cannabinoids

Vancouver, british columbia, sept. 13, 2021 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that it has entered into a definitive agreement (“definitive agreement”) to acquire baymedica inc. (“baymedica”), a private company based in the us that specializes in the manufacturing and commercialization of rare cannabinoids. the definitive agreement follows a previously signed letter of intent (the "loi") announced on june 29, 2021. the transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks.
INM Ratings Summary
INM Quant Ranking